Formula I Compounds Inhibiting HCV NS5B Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, particularly for genotype 1, which has a poor treatment response and severe side effects, and there is a need for antiviral drugs with improved efficacy and safety profiles.
Innovation Solution
Development of novel compounds of formula I, which are effective against HCV, including pharmaceutically acceptable salts, that target specific mechanisms such as binding, inhibition efficacy, target selectivity, solubility, safety profiles, and bioavailability, specifically designed to inhibit HCV NS5B protein and other viral functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (pegylated alpha-interferon and oral ribavirin) are used for HCV genotype 1, then treatment coverage is provided, but treatment response is poor (only 50% sustained virologic response) and severe side effects occur
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (formula I with various substituents R1-R6) that change the pharmacological parameters of HCV treatment. These structural modifications aim to improve viral inhibition efficacy while reducing toxic side effects compared to existing interferon and ribavirin therapies
Solution Approach 2:
The patent employs composite materials principle by creating hybrid compounds that combine multiple functional groups and structural elements within formula I. These composite molecular structures integrate different pharmacophores to achieve both high antiviral activity against HCV genotype 1 and improved safety profiles
2Reliability
If blood screening methods are introduced to prevent HCV transmission, then transmission via transfusion is reduced, but transmission via injection drug use becomes the primary risk factor
Solution Approach 1:
The patent applies inversion by shifting the treatment approach from managing transmission risks to directly targeting viral replication mechanisms. Instead of focusing on prevention of transmission routes, the novel compounds directly inhibit HCV NS5B polymerase and other viral functions, making treatment effective regardless of transmission source
3Reliability
If novel compounds of formula I are developed to inhibit HCV NS5B, then antiviral efficacy is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into manageable components: core formula I structure, variable substituent groups (R1-R6), and specific embodiment variations. This modular approach allows systematic optimization of antiviral efficacy while managing development complexity through structured chemical series
Solution Approach 2:
The patent employs universality by designing formula I compounds with multiple active substituents that can simultaneously target different viral functions (NS5B polymerase inhibition, protease inhibition, entry blockade). This multi-functional molecular design achieves broad antiviral efficacy against HCV genotypes through a single compound class
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.